Clinical

Dataset Information

0

BKM120 in Cancers With PIK3CA Activating Mutations


ABSTRACT: In people whos cancers have a PIK3CA mutation, this trial will be evaluating the drug BKM120 as a possible treatment. BKM120 works by blocking the phosphatidylinositol-3-kinase (PI3K)pathway, thereby inhibiting tumor growth and survival. The purpose of this study is to learn if the study drug BKM120 can shrink or slow the growth of your tumor. The safety of BKM120 will also be studied. Your physical state, symptoms, change in the size of your tumor, and laboratory findings obtained while you are on study will help the research team decide if BKM120 is safe and effective in patients with advanced cancers.

DISEASE(S): Lung Cancer,Advanced Solid Tumors,Colorectal Cancer,Breast Cancer,Solid Tumors,Cholangiocarcinoma

PROVIDER: 2117958 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2020-12-31 | GSE148949 | GEO
2014-12-31 | GSE57380 | GEO
2018-05-29 | GSE98824 | GEO
2021-01-27 | GSE149720 | GEO
2013-06-20 | E-GEOD-43037 | biostudies-arrayexpress
| PRJNA626611 | ENA
2013-06-20 | GSE43037 | GEO
2012-06-30 | E-GEOD-33643 | biostudies-arrayexpress
2011-08-01 | E-GEOD-27691 | biostudies-arrayexpress
2019-06-18 | GSE109679 | GEO